Arcus Biosciences

Yahoo Finance • 2 months ago

Arcus Biosciences’ SWOT analysis: stock’s potential hinges on HIF-2alpha data

Arcus Biosciences, Inc. (NASDAQ:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, has been garnering significant attention from investors and analysts alike. The company’s stock performance and future pr... Full story

Yahoo Finance • 2 months ago

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per share, beating the consensus of $1.94. Sal... Full story

Yahoo Finance • 2 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig in first-line metastatic ccRCC, have be... Full story

Yahoo Finance • 2 months ago

Arcus Biosciences' SWOT analysis: HIF-2alpha program drives stock outlook

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its promising pipeline and recent developments... Full story

Yahoo Finance • 3 months ago

Arcus' pancreatic cancer drug quemliclustat receives FDA orphan status

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a biotechnology company with a strong balance sheet showing more cash than debt according to InvestingPro data, announced Thursday that its investigational CD73 inhibitor quemliclustat... Full story

Yahoo Finance • 3 months ago

Arcus Biosciences February 2025 slides: oncology pipeline progresses despite Q1 miss

Introduction & Market Context Arcus Biosciences (NYSE:RCUS) presented its corporate update on February 25, 2025, showcasing its oncology pipeline and development strategy. The presentation comes at a challenging time for the clinical-stag... Full story

Yahoo Finance • 4 months ago

Arcus Biosciences' SWOT analysis: promising cancer therapy stock faces pivotal year

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biopharmaceutical company focused on developing innovative cancer therapies, stands at a critical juncture in its journey to bring novel treatments to market. With its lead candidate, casdatifa... Full story

Yahoo Finance • 5 months ago

Q1 2025 Arcus Biosciences Inc Earnings Call

Participants Pia Eaves; Vice President of Investor Relations & Strategy; Arcus Biosciences Inc Terry Rosen; Chairman of the Board, Chief Executive Officer, Co-Founder; Arcus Biosciences Inc Richard Markus; Chief Medical Officer; Arcus B... Full story

Yahoo Finance • last year

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., October 09, 2024--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, to... Full story

Yahoo Finance • last year

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus'... Full story

Yahoo Finance • 2 years ago

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announce... Full story

Yahoo Finance • 2 years ago

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] T... Full story

Yahoo Finance • 3 years ago

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update

Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by year-end; Arcus and Gilead Sciences continue to expand their late-stage clinical program for domvanalimab with the goal of es... Full story

Yahoo Finance • 3 years ago

Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer

A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.... Full story